INmune Bio, Inc.
INMB
$7.30
-$0.20-2.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 257.14% | -100.00% | -- | -- | -63.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 257.14% | -100.00% | -- | -- | -63.16% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 257.14% | -100.00% | -- | -- | -63.16% |
| SG&A Expenses | -0.94% | -11.92% | -14.19% | 21.78% | 0.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.75% | 12.61% | 43.34% | 52.78% | 70.73% |
| Operating Income | 10.09% | -12.98% | -44.07% | -53.88% | -71.52% |
| Income Before Tax | 11.66% | -9.63% | -41.22% | -49.92% | -68.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.66% | -9.63% | -41.22% | -49.92% | -68.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.66% | -9.63% | -41.22% | -49.92% | -68.68% |
| EBIT | 10.09% | -12.98% | -44.07% | -53.88% | -71.52% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 29.22% | 11.17% | -25.99% | -39.33% | -67.93% |
| Normalized Basic EPS | 29.22% | 11.18% | -25.98% | -39.36% | -67.97% |
| EPS Diluted | 29.22% | 11.17% | -25.99% | -39.33% | -67.93% |
| Normalized Diluted EPS | 29.22% | 11.18% | -25.98% | -39.36% | -67.97% |
| Average Basic Shares Outstanding | 24.80% | 23.44% | 12.09% | 7.59% | 0.45% |
| Average Diluted Shares Outstanding | 24.80% | 23.44% | 12.09% | 7.59% | 0.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |